A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

NCT00001669 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: rhIGF-1 (CEP-151)

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)